- Home
- PALI vs PROF Comparison
PALI vs PROF Comparison
Compare PALI & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PALI | PROF |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.2M | 238.1M |
| IPO Year | 2019 | 2017 |
Fundamental Metrics
Financial Performance| Metric | PALI | PROF |
|---|---|---|
| Price | $2.08 | $7.03 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | $11.29 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 5.1M | 155.3K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 97.06 | 25.89 |
| EPS | N/A | ★ 1.41 |
| Revenue | $260,000.00 | ★ $16,098,000.00 |
| Revenue This Year | N/A | $92.40 |
| Revenue Next Year | N/A | $64.10 |
| P/E Ratio | ★ N/A | $4.83 |
| Revenue Growth | ★ 1500.39 | 50.73 |
| 52 Week Low | $0.55 | $3.92 |
| 52 Week High | $2.86 | $8.95 |
Technical Indicators
Market Signals| Indicator | PALI | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 48.97 | 59.36 |
| Support Level | $1.57 | $7.00 |
| Resistance Level | $2.09 | $7.97 |
| Average True Range (ATR) | 0.22 | 0.41 |
| MACD | 0.00 | 0.08 |
| Stochastic Oscillator | 26.29 | 86.33 |
Price Performance
Historical ComparisonAbout PALI Palisade Bio Inc.
Palisade Bio Inc is a clinical-stage biopharma company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. Its portfolio consists of a PALI-2108 for the treatment of IBD, including UC and CD, and is researching PALI-1908.
About PROF Profound Medical Corp.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.